Cargando…

Plasma Aβ analysis using magnetically-labeled immunoassays and PET (18)F-florbetapir binding in non-demented patients with major depressive disorder

An increased level of brain amyloid deposition and a decreased level of cerebral spinal fluid (CSF) Aβ42 are currently considered reliable biomarkers of Alzheimer’s disease (AD); however, the usefulness of plasma Aβ levels are not well-established. This study investigated the relationships between p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Kuan-Yi, Hsiao, Ing-Tsung, Chen, Chia-Hsiang, Liu, Chia-Yih, Hsu, Jung-Lung, Huang, Sheng-Yao, Yen, Tzu-Chen, Lin, Kun-Ju
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5807319/ https://www.ncbi.nlm.nih.gov/pubmed/29426824 http://dx.doi.org/10.1038/s41598-018-21140-3

Ejemplares similares

Author Correction: Plasma Aβ analysis using magnetically-labeled immunoassays and PET (18)F-florbetapir binding in non-demented patients with major depressive disorder
por: Wu, Kuan-Yi, et al.
Publicado: (2019)

Operationalizing the centiloid scale for [(18)F]florbetapir PET studies on PET/MRI
por: Coath, William, et al.
Publicado: (2023)

Beta-amyloid deposition in patients with major depressive disorder with differing levels of treatment resistance: a pilot study
por: Li, Peng, et al.
Publicado: (2017)

Diversity of neurodegenerative pathophysiology in nondemented patients with major depressive disorder: Evidence of cerebral amyloidosis and hippocampal atrophy
por: Wu, Kuan‐Yi, et al.
Publicado: (2018)

Radiation dosimetry of florbetapir F 18
por: Joshi, Abhinay D, et al.
Publicado: (2014)

Decreased Cerebral Amyloid-β Depositions in Patients With a Lifetime History of Major Depression With Suspected Non-Alzheimer Pathophysiology
por: Wu, Kuan-Yi, et al.
Publicado: (2022)

[(18)F]Florbetapir PET/MR imaging to assess demyelination in multiple sclerosis
por: Carotenuto, Antonio, et al.
Publicado: (2019)

(18)F-florbetapir PET/MRI for quantitatively monitoring demyelination and remyelination in acute disseminated encephalomyelitis
por: Zhang, Min, et al.
Publicado: (2019)

Hybrid (18)F-florbetapir PET/MRI for assessing myelin recovery in GFAP-A patients
por: Meng, Huanyu, et al.
Publicado: (2022)

(18)F-THK5351 PET imaging in patients with progressive supranuclear palsy: associations with core domains and diagnostic certainty
por: Hsu, Jung-Lung, et al.
Publicado: (2020)

(18)F-florbetapir PET as a marker of myelin integrity across the Alzheimer’s disease spectrum
por: Moscoso, Alexis, et al.
Publicado: (2021)

Author Correction: (18)F-THK5351 PET imaging in patients with progressive supranuclear palsy: associations with core domains and diagnostic certainty
por: Hsu, Jung-Lung, et al.
Publicado: (2021)

A Novel Individual Metabolic Brain Network for 18F-FDG PET Imaging
por: Huang, Sheng-Yao, et al.
Publicado: (2020)

Dual-phase [18F]florbetapir in frontotemporal dementia
por: Asghar, Michael, et al.
Publicado: (2018)

Florbetapir F 18 amyloid PET and 36-month cognitive decline:a prospective multicenter study
por: Doraiswamy, P M, et al.
Publicado: (2014)

PET imaging of 18F-florbetapir in cognitively impaired individuals: Lack of activity within the cerebellar cortex
por: Meyer, Michael A., et al.
Publicado: (2018)

Using PET with (18)F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment
por: Camus, V., et al.
Publicado: (2012)

A Routine PET/CT Protocol with Streamlined Calculations for Assessing Cardiac Amyloidosis Using (18)F-Florbetapir
por: Osborne, Dustin R., et al.
Publicado: (2015)

Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease
por: Mattsson, Niklas, et al.
Publicado: (2014)

Cortical florbetapir-PET amyloid load in prodromal Alzheimer’s disease patients
por: Saint-Aubert, Laure, et al.
Publicado: (2013)

(18)F-florbetapir PET/MRI for quantitatively monitoring myelin loss and recovery in patients with multiple sclerosis: A longitudinal study
por: Zhang, Min, et al.
Publicado: (2021)

Brain Imaging of Vesicular Monoamine Transporter Type 2 in Healthy Aging Subjects by (18)F-FP-(+)-DTBZ PET
por: Lin, Kun-Ju, et al.
Publicado: (2013)

Pilot Study of F18-Florbetapir in the Early Evaluation of Cardiac Amyloidosis
por: Sperry, Brett W., et al.
Publicado: (2021)

Quantitative study of (18)F-(+)DTBZ image: comparison of PET template-based and MRI based image analysis
por: Jung Lung, Hsu, et al.
Publicado: (2018)

PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with (18)F-AV-133 (florbenazine) in patients with Alzheimer’s disease and Lewy body disorders
por: Siderowf, Andrew, et al.
Publicado: (2014)

Visual reading for [(18)F]Florzolotau ([(18)F]APN-1607) tau PET imaging in clinical assessment of Alzheimer’s disease
por: Lin, Huan-Chun, et al.
Publicado: (2023)

Multi-contrast attenuation map synthesis for PET/MR scanners: assessment on FDG and Florbetapir PET tracers
por: Burgos, Ninon, et al.
Publicado: (2015)

Florbetapir Regional Distribution in Cerebral Amyloid Angiopathy and Alzheimer’s Disease: A PET Study
por: Planton, Mélanie, et al.
Publicado: (2020)

Tracer‐specific reference tissues selection improves detection of (18)F‐FDG, (18)F‐florbetapir, and (18)F‐flortaucipir PET SUVR changes in Alzheimer's disease
por: Li, Yanxiao, et al.
Publicado: (2022)

Clinical impact of amyloid PET using (18)F-florbetapir in patients with cognitive impairment and suspected Alzheimer’s disease: a multicenter study
por: Matsuda, Hiroshi, et al.
Publicado: (2022)

Non-invasive Standardised Uptake Value for Verification of the Use of Previously Validated Reference Region for [(18)F]Flortaucipir and [(18)F]Florbetapir Brain PET Studies
por: de Vries, Bart M., et al.
Publicado: (2021)

Lacrimal gland uptake on F-18 florbetapir amyloid positron emission tomography scan
por: Itani, Malak, et al.
Publicado: (2017)

Quantification of [(18)F]florbetapir: A test–retest tracer kinetic modelling study
por: Golla, Sandeep SV, et al.
Publicado: (2018)

Classification of negative and positive (18)F-florbetapir brain PET studies in subjective cognitive decline patients using a convolutional neural network
por: de Vries, Bart Marius, et al.
Publicado: (2020)

Head-to-head comparison of relative cerebral blood flow derived from dynamic [(18)F]florbetapir and [(18)F]flortaucipir PET in subjects with subjective cognitive decline
por: Tuncel, Hayel, et al.
Publicado: (2023)

Extracardiac (18)F-florbetapir imaging in patients with systemic amyloidosis: more than hearts and minds
por: Wagner, T., et al.
Publicado: (2018)

MAPT rs242557 variant is associated with hippocampus tau uptake on (18)F-AV-1451 PET in non-demented elders
por: Shen, Xue-Ning, et al.
Publicado: (2019)

APOE and BCHE as modulators of cerebral amyloid deposition: a florbetapir PET genome-wide association study
por: Ramanan, Vijay K., et al.
Publicado: (2013)

A consecutive case series experience with [(18) F] florbetapir PET imaging in an urban dementia center: impact on quality of life, decision making, and disposition
por: Mitsis, Effie M, et al.
Publicado: (2014)

The use of back propagation neural networks and (18)F-Florbetapir PET for early detection of Alzheimer’s disease using Alzheimer’s Disease Neuroimaging Initiative database
por: Ozsahin, Ilker, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_714jbj7lcbl89pdd3qhgtaeaq2